Hepatic drug metabolism and transport in patients with kidney disease.
about
Nicotine chemistry, metabolism, kinetics and biomarkersA Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDEffects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver.Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance.Effect of renal impairment on the pharmacokinetics of bupropion and its metabolitesEffects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.Antimicrobial-associated QT interval prolongation: pointes of interest.Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum.Anesthetic management in parturients with chronic kidney disease undergoing elective Caesarean delivery: Our experience of nine cases.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.Current understanding of drug disposition in kidney disease.Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.Consequences of renal failure on non-renal clearance of drugs.Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.Downregulation of hepatic acetylation of drugs in chronic renal failure.Design, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney function.Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease.Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis.Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.Pharmacokinetics of Aliskiren in Patients with End-Stage Renal Disease Undergoing Haemodialysis
P2860
Q24632647-F962F9CA-B19E-4209-B26B-6803B3A41540Q28087621-ADFD3093-353C-4CE6-8EC5-41A52887B70CQ34726696-ABA20439-F83E-4501-B52A-A29936864A5FQ35566515-32EE54F9-C386-46AC-8360-1DA89F51A2C2Q36024598-8564AC34-6520-4AEA-A0F3-91B86F8F633DQ36024890-57D2F960-5359-4436-A7A9-65ABB759E619Q36634909-EA53B1FA-2A5B-4A89-A2EB-FCE859B1B212Q36655034-6E9D92CE-461F-4488-AB09-B2E010469AFAQ37391009-D0F06E3D-F577-4F3B-A7E3-3E8574323710Q37589774-CEE6B359-8A02-445F-82DC-EA327EFB80DFQ37960638-A5A2593D-A481-45EA-B582-C2E486CDB7CFQ37964754-3E3243A8-A715-4656-BA39-7368384970C2Q37974644-7EAA1791-2901-4373-9148-7696CCA0A4F1Q38153196-E7F6FF8E-A178-42BB-83C5-FE32268C366BQ38214827-FE21184B-EE01-47CE-BD57-49F587272AC3Q38222867-87271141-FC3B-4632-8EF0-C1BD32050E92Q39588785-36C9D59F-2388-455E-9CF0-0949C439FF72Q39664155-2AC4D476-E498-4666-B828-15D170239F8FQ42552831-F56879F1-75B8-4A49-A488-38A2C7AC77FDQ45901623-EBAFE1E9-FD73-4BF9-99B7-6516C16BB4D4Q45958144-66A15C92-498D-41E9-B5BB-ABD2319CFA78Q50108575-BF3E4372-D8A2-4094-B807-6B2F397F828FQ56987287-C89AA5AF-304B-4BC8-B9C7-9AFD8979B688
P2860
Hepatic drug metabolism and transport in patients with kidney disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Hepatic drug metabolism and transport in patients with kidney disease.
@ast
Hepatic drug metabolism and transport in patients with kidney disease.
@en
type
label
Hepatic drug metabolism and transport in patients with kidney disease.
@ast
Hepatic drug metabolism and transport in patients with kidney disease.
@en
prefLabel
Hepatic drug metabolism and transport in patients with kidney disease.
@ast
Hepatic drug metabolism and transport in patients with kidney disease.
@en
P1476
Hepatic drug metabolism and transport in patients with kidney disease
@en
P2093
Gary R Matzke
Thomas D Nolin
P304
P356
10.1016/J.AJKD.2003.07.019
P577
2003-11-01T00:00:00Z